Found 146 Enz. Inhib. hit(s) with all data for entry = 1277 
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
